ImportRefusal LogoImportRefusal

STIRITI AYUR THERAPIES PRIVATE

⚠️ Moderate Risk

FEI: 3012527927 • ANDHRA PRADESH • INDIA

FEI

FEI Number

3012527927

📍

Location

ANDHRA PRADESH

🇮🇳

Country

INDIA
🏢

Address

SY NO 179-180 CHEEKATIM, , ANDHRA PRADESH, , India

Moderate Risk

FDA Import Risk Assessment

35.6
LowModerateHighCritical

This firm has a moderate history of FDA import refusals. Some attention may be warranted.

Statistics

3
Total Refusals
4
Unique Violations
1/9/2024
Latest Refusal
11/27/2023
Earliest Refusal

Score Breakdown

Violation Severity
42.5×40%
Refusal Volume
22.3×30%
Recency
44.8×20%
Frequency
30.0×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

23003×

DIETARYLBL

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it is a dietary supplement that appears to be misbranded within the meaning of Section 403(s)(2)(B) of the FD&C Act in that the label or labeling fails to identify the product by using the term "dietary supplement", which term may be modified with the name of such an ingredient.

2603×

FALSE

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(a)(1 ) of the FD&C Act in that the labeling is false or misleading in any particular.

38643×

NCONTACT

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it is a dietary supplement that appears to be misbranded within the meaning of Section 403(y) of the FD&C Act in that the dietary supplement label fails to bear a domestic address or phone number through which the responsible person (as described in section 761 of the FD&C Act) may receive a report of a serious adverse event with such dietary supplement.

4823×

NUTRIT LBL

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information.

Refusal History

DateProductViolationsDivision
1/9/2024
54YYB99VITAMIN, MINERAL, PROTEINS AND UNCONVENTIONAL DIETARY SPECIALITIES FOR HUMANS AND ANIMALS, N.E.C.
2300DIETARYLBL
260FALSE
3864NCONTACT
482NUTRIT LBL
Division of Southeast Imports (DSEI)
1/3/2024
54HEY99FATS AND LIPID SUBSTANCES, N.E.C.
2300DIETARYLBL
260FALSE
3864NCONTACT
482NUTRIT LBL
Division of Southeast Imports (DSEI)
11/27/2023
54YYY99VITAMIN, MINERAL, PROTEINS AND UNCONVENTIONAL DIETARY SPECIALITIES FOR HUMANS AND ANIMALS, N.E.C.
2300DIETARYLBL
260FALSE
3864NCONTACT
482NUTRIT LBL
Division of Southeast Imports (DSEI)

Frequently Asked Questions

What is STIRITI AYUR THERAPIES PRIVATE's FDA import refusal history?

STIRITI AYUR THERAPIES PRIVATE (FEI: 3012527927) has 3 FDA import refusal record(s) in our database, spanning from 11/27/2023 to 1/9/2024.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. STIRITI AYUR THERAPIES PRIVATE's FEI number is 3012527927.

What types of violations has STIRITI AYUR THERAPIES PRIVATE received?

STIRITI AYUR THERAPIES PRIVATE has been cited for 4 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about STIRITI AYUR THERAPIES PRIVATE come from?

All FDA import refusal data for STIRITI AYUR THERAPIES PRIVATE is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.